Skip to main content
Premium Trial:

Request an Annual Quote

Progenity: Surbhi Sarna

Progenity has appointed Surbhi Sarna to its board of directors effective July 1. She is currently a visiting partner at Y Combinator. Sarna founded nVision Medical and acted as CEO of the medical device company until it was acquired by Boston Scientific in 2018, where she led commercial efforts for nVision until 2020. She previously served in healthcare engineering roles at BioCardia and Abbott Vascular.

Sarna is a board member at medical device company Penumbra and on its audit and nominating and corporate governance committees. She's also on the board of trustees at Astia, which provides access to capital and networks to women entrepreneurs. 

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.